CN1686423A - Medicinal composition containing scutellaria glucoside and bupleurum and its preparation method - Google Patents
Medicinal composition containing scutellaria glucoside and bupleurum and its preparation method Download PDFInfo
- Publication number
- CN1686423A CN1686423A CN 200510067854 CN200510067854A CN1686423A CN 1686423 A CN1686423 A CN 1686423A CN 200510067854 CN200510067854 CN 200510067854 CN 200510067854 A CN200510067854 A CN 200510067854A CN 1686423 A CN1686423 A CN 1686423A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- radix bupleuri
- group
- ethanol
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims description 26
- 239000000203 mixture Substances 0.000 title claims description 19
- 241000202726 Bupleurum Species 0.000 title abstract description 5
- 241000207929 Scutellaria Species 0.000 title 1
- 229930182478 glucoside Natural products 0.000 title 1
- 150000008131 glucosides Chemical class 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract description 29
- 239000000284 extract Substances 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 49
- 239000008194 pharmaceutical composition Substances 0.000 claims description 29
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 claims description 25
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 claims description 25
- 229960003321 baicalin Drugs 0.000 claims description 25
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 claims description 25
- 239000007788 liquid Substances 0.000 claims description 20
- 239000000843 powder Substances 0.000 claims description 15
- 238000001035 drying Methods 0.000 claims description 14
- 229920002472 Starch Polymers 0.000 claims description 10
- 238000002347 injection Methods 0.000 claims description 10
- 239000007924 injection Substances 0.000 claims description 10
- 239000008107 starch Substances 0.000 claims description 10
- 235000019698 starch Nutrition 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000007910 chewable tablet Substances 0.000 claims description 2
- 229940068682 chewable tablet Drugs 0.000 claims description 2
- 239000007919 dispersible tablet Substances 0.000 claims description 2
- 239000007938 effervescent tablet Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 229940023488 pill Drugs 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000007909 solid dosage form Substances 0.000 claims 1
- 206010004542 Bezoar Diseases 0.000 abstract 1
- 206010057190 Respiratory tract infections Diseases 0.000 abstract 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 abstract 1
- XDQITMCFPPPMBC-TUANDBMESA-N scutelloside Natural products OC[C@H]1O[C@@H](O[C@@H]2O[C@@H]3C[C@H]4[C@H](O)[C@@H](O)[C@@](O)(CO3)[C@@H]24)[C@H](O)[C@@H](O)[C@@H]1O XDQITMCFPPPMBC-TUANDBMESA-N 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 12
- 238000010438 heat treatment Methods 0.000 description 10
- 206010022000 influenza Diseases 0.000 description 10
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 241000700605 Viruses Species 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 230000036760 body temperature Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000002481 ethanol extraction Methods 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 238000011026 diafiltration Methods 0.000 description 4
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 240000004534 Scutellaria baicalensis Species 0.000 description 2
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000007667 floating Methods 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229940124579 cold medicine Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 229940071462 oralone Drugs 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Center 01 02 03 04 05 adds up to | Go into to organize case load | Case load comes off | Reject case load | Finish case load | ||||||||||||
The A group | The B group | The C group | Add up to | The A group | The B group | The C group | Add up to | The A group | The B group | The C group | Add up to | The A group | The B group | The C group | Add up to | |
??24 ??24 ??24 ??24 ??24 ??120 | ??24 ??24 ??24 ??24 ??24 ??120 | ??24 ??24 ??24 ??24 ??24 ??120 | ??72 ??72 ??72 ??72 ??72 ??360 | ??0 ??3 ??0 ??0 ??0 ??3 | ??1 ??5 ??0 ??0 ??2 ??8 | ??1 ??4 ??0 ??0 ??2 ??7 | ??2 ??12 ??0 ??0 ??4 ??18 | ??1 ??0 ??0 ??0 ??0 ??1 | ??2 ??0 ??0 ??0 ??0 ??2 | ??0 ??0 ??0 ??0 ??0 ??0 | ??3 ??0 ??0 ??0 ??0 ??3 | ??23 ??21 ??24 ??24 ??24 ??116 | ??21 ??19 ??24 ??24 ??22 ??110 | ??23 ??20 ??24 ??24 ??22 ??113 | ??67 ??60 ??72 ??72 ??68 ??339 |
The center | Meet the scheme collection | The intentional analysis collection | The safety collection | |||||||||
The A group | The B group | The C group | Add up to | The A group | The B group | The C group | Add up to | The A group | The B group | The C group | Add up to | |
????01 ????02 ????03 ????04 ????05 | ????23 ????21 ????24 ????24 ????24 | ????21 ????49 ????24 ????24 ????22 | ????23 ????20 ????24 ????24 ????22 | ????67 ????60 ????72 ????72 ????68 | ????23 ????22 ????24 ????24 ????24 | ????22 ????21 ????24 ????24 ????22 | ????23 ????20 ????24 ????24 ????22 | ????68 ????63 ????72 ????72 ????68 | ????24 ????24 ????24 ????24 ????24 | ????24 ????24 ????24 ????24 ????24 | ????24 ????24 ????24 ????24 ????24 | ????72 ????72 ????72 ????72 ????72 |
Add up to | ????116 | ??110 | ????113 | ????339 | ????117 | ????113 | ????113 | ????343 | ????120 | ????120 | ????120 | ????360 |
Group | ??n | Recovery from illness | Produce effects | Effectively | Invalid | Total obvious effective rate | Total effective rate | ||||
??n | ??% | ??n | ????% | ????n | ????% | ????n | ??% | ||||
A group B group C group | ??116 ??110 ??113 | ??50 ??46 ??29 | ??43.10 ??41.82 ??25.66 | ??50 ??50 ??53 | ??43.10 ??45.45 ??46.90 | ????13 ????11 ????30 | ????11.21 ????10.00 ????26.55 | ????3 ????3 ????1 | ??2.59 ??2.73 ??0.88 | ?86.20 ?87.27 ?72.59 | ?97.41 ?97.27 ?99.12 |
Group | ??n | Recovery from illness | Produce effects | Effectively | Invalid | Total obvious effective rate | Total effective rate | ||||
??N | ?% | ??n | ?% | ????n | ????% | ????n | ??% | ||||
The A group | ??116 | ????50 | ?46.55 | ??50 | ?43.10 | ????9 | ????7.76 | ????3 | ???2.59 | ?89.65 | ?97.41 |
B group C group | ?110 ?113 | ?48 ?29 | ?43.64 ?25.66 | ?46 ?53 | ?41.82 ?46.90 | ????13 ????30 | ????11.00 ????26.55 | ????3 ????1 | ??2.73 ??0.88 | ??85.46 ??72.59 | ??97.27 ??99.12 |
Group | ??n | X ± S before the treatment | Treatment back x ± S | Difference x ± S | ????F | ????P |
A group B group C group | ?? ??116 ? ? ??110 ? ? ??113 | ??37.85± ????0.41 ??37.88± ? ????0.38 ??37.95± ? ????0.43 | ??36.82± ? ????0.42 ??36.84± ? ????0.35 ??36.89± ? ????0.48 | ????1.031± ? ????????0.432 ????1.050± ? ????????0.424 ????1.028± ? ????????0.398 | ? ? ? ?? ??0.09 | ? ? ? ?? ??0.915 |
Symptom heating slight chill pharyngalgia | Group A group B group C group A group B group C group | ?n ? ?? ?116 ?110 ?113 ?116 ?110 ?113 | Before controlling | In controlling | After controlling | |||||||||
Do not have 000000 | Light by 48 36 42 69 54 59 | In 52 57 49 37 41 44 | Weigh 16 17 22 10 15 10 | Do not have 69 58 61 18 21 17 | Light by 38 43 38 91 72 80 | In 99 13 7 17 14 | Weigh 001002 | Do not have 108 101 93 81 73 59 | Light by 55 18 34 37 49 | In 341104 | Weigh 001001 |
Group | ????n | Before controlling | After controlling | In the group | Between group | |||
Normally | Red | Normally | Red | ????P * | ??X 2 | ????P | ||
A group B group C group | ??116 ??110 ??113 | ????4 ????4 ????4 | ????112 ????106 ????109 | ????82 ????76 ????66 | ????34 ????34 ????47 | ????0.00 ????0.00 ????0.00 | ?4.512 | ????0.105 |
Group | ????n | Before controlling | After controlling | In the group | Between group | |||||
Normally | The book Huang | Other | Normally | The book Huang | Other | ??P * | ??X2 | ??P |
A group B group C group | ?116 ?110 ?113 | ?7 ?8 ?8 | ?109 ?102 ?105 | ?0 ?0 ?0 | ?80 ?77 ?75 | ?36 ?33 ?38 | ?0 ?0 ?0 | ?0.00 ?0.00 ?0.00 | ? ??0.362 | ? ??0.834 |
Group | ??n | Before controlling | After controlling | In the group | P between group * | |||
Normally | Floating number | Normally | Floating number | ????X 2 | ????P | |||
A group B group C group | ??116 ??110 ??113 | ????34 ????36 ????32 | ????82 ????74 ????81 | ????111 ????105 ????95 | ????5 ????5 ????18 | ? ? ????71.34 | ????0.00 ????0.00 ????0.00 | ? ???0.003 |
Group | ??n | Before controlling | After controlling | In the group | Between group | ||||
Negative (%) | Positive (%) | Negative (%) | Positive (%) | ?Z | ??P | ?X 2 | ?P | ||
A group B group C group | ?93 ?89 ?94 | 65(69.89) 59(66.29) 64(68.82) | 28(30.11) 30(23.71) 29(68.82) | ??89(95.70) ??86(96.63) ??86(31.18) | 4(4.30) 3(3.37) 8(7.53) | ?4.899 ?5.196 ?4.690 | ??0.00 ??0.00 ??0.00 | ? ?1.807 | ? ?0.405 |
Group | ??n | ???~12 | ???~24 | ???~48 | ???~72 | Not onset | ??X 2 | ????P |
A group B group C group | ??116 ??110 ??113 | ????83 ????86 ????77 | ????16 ????13 ????18 | ????9 ????6 ????10 | ????1 ????1 ????1 | ????7 ????7 ????7 | ? ??1.445 | ? ??0.695 |
Group | ????n | ?? x±S | ????F | ????P |
A group B group C group | ????109 ????105 ????107 | ??10.29±11.80 ??9.67±8.80 ??11.73±13.32 | ? ????0.90 | ? ????0.41 |
Group | ??n | ??~12 | ??~24 | ??~48 | ??~72 | Not onset | ??X 2 | ???P |
A group B group | ??116 ??110 | ??53 ??37 | ??20 ??20 | ??15 ??22 | ??7 ??14 | ????21 ????17 | ??9.32 | ???0.32 |
The C group | ????113 | ????44 | ????19 | ????16 | ????8 | ????26 |
Group | ????n | ????? x±S | ????F | ????P |
A group B group C group | ????106 ????95 ????90 | ????25.59±27.92 ????26.17±21.98 ????21.97±20.72 | ? ????0.84 | ? ????0.43 |
Claims (14)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100678542A CN100512796C (en) | 2005-04-28 | 2005-04-28 | Medicinal composition containing scutellaria glucoside and bupleurum and its preparation method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100678542A CN100512796C (en) | 2005-04-28 | 2005-04-28 | Medicinal composition containing scutellaria glucoside and bupleurum and its preparation method |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1686423A true CN1686423A (en) | 2005-10-26 |
CN100512796C CN100512796C (en) | 2009-07-15 |
Family
ID=35304465
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100678542A Active CN100512796C (en) | 2005-04-28 | 2005-04-28 | Medicinal composition containing scutellaria glucoside and bupleurum and its preparation method |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100512796C (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100420456C (en) * | 2006-03-14 | 2008-09-24 | 北京国丹药物技术开发有限公司 | Compounded Radix Bupleuri enema preparation and preparing method |
CN102641333A (en) * | 2012-04-11 | 2012-08-22 | 河南灵佑药业有限公司 | Sugar-free type Chaihuang granules and preparing method thereof |
CN102106884B (en) * | 2009-12-25 | 2013-08-21 | 财团法人工业技术研究院 | Medicinal composition having immunity-regulating function |
US8597693B2 (en) | 2010-07-01 | 2013-12-03 | Industrial Technology Research Institute | Pharmaceutical composition with immunomodulating function |
CN106309522A (en) * | 2016-08-24 | 2017-01-11 | 扬子江药业集团上海海尼药业有限公司 | Chaifei Qingning capsule and preparing method thereof |
-
2005
- 2005-04-28 CN CNB2005100678542A patent/CN100512796C/en active Active
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100420456C (en) * | 2006-03-14 | 2008-09-24 | 北京国丹药物技术开发有限公司 | Compounded Radix Bupleuri enema preparation and preparing method |
CN102106884B (en) * | 2009-12-25 | 2013-08-21 | 财团法人工业技术研究院 | Medicinal composition having immunity-regulating function |
US8597693B2 (en) | 2010-07-01 | 2013-12-03 | Industrial Technology Research Institute | Pharmaceutical composition with immunomodulating function |
CN102641333A (en) * | 2012-04-11 | 2012-08-22 | 河南灵佑药业有限公司 | Sugar-free type Chaihuang granules and preparing method thereof |
CN106309522A (en) * | 2016-08-24 | 2017-01-11 | 扬子江药业集团上海海尼药业有限公司 | Chaifei Qingning capsule and preparing method thereof |
CN106309522B (en) * | 2016-08-24 | 2017-07-28 | 扬子江药业集团上海海尼药业有限公司 | Clear Yiganning capsule of bavin a kind of reed mentioned in ancient books and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
CN100512796C (en) | 2009-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009149585A1 (en) | Compositions for reducing blood glucose level and uses thereof | |
CN1686423A (en) | Medicinal composition containing scutellaria glucoside and bupleurum and its preparation method | |
CN101732668B (en) | Preparation method of Chinese medicinal composition for treating urinary system infection | |
CN101032547A (en) | Anti-inflammatory and antivirotic medicine composition | |
CN1425447A (en) | Traditional Chinese medicine composition for curing child's dyspepsia and cough and its preparing method | |
CN110623998B (en) | Traditional Chinese medicine composition for diabetic peripheral neuropathy and application thereof | |
CN101002836B (en) | Use of the extractive of radix cynanchi bungei total glucoside | |
CN1686424A (en) | Medicinal composition containing scutellaria and bupleurum and its preparation method | |
CN102228547B (en) | Application of traditional Chinese medicine composition in preparing medicaments treating pancreatitis and/or cholecystitis | |
CN1857697A (en) | Compound Chinese medicine Anxuekang and its preparing method | |
CN101041037A (en) | Drug for curing diabetes and nephropathy and its preparing method | |
CN1823982A (en) | Chinese medicinal preparation for liver soothing and speen fortifying and its manufacturing method | |
CN1846775A (en) | New medicinal use of Chinese medicine nutmeg and its extract | |
CN1421229A (en) | Chinese medicine for treating hepatocirrhosis, hepatitis and liver cancer | |
CN103520684B (en) | Traditional Chinese medicine compound for reducing blood sugar | |
CN105727089A (en) | Application of medicine composition containing folium artemisiae argyi to preparing medicine for treating irritable bowel syndrome | |
CN1237998C (en) | Effervescence tablet for treating children's cough and asthma and its preparation | |
CN113058013A (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
CN1839956A (en) | Pharmaceutical composition containing curcumin and its formulation | |
CN104352672A (en) | Tortoise plastron-containing traditional Chinese medicine composition for treating diabetes | |
CN103316103A (en) | Coccidian-expelling and dysentery-stopping mixture for livestock and preparation method thereof | |
CN1526441A (en) | Agastache capsule for restoring healthy energy andits prepn and application | |
CN101322762B (en) | Medicinal composition for treating diabetes | |
CN101391076A (en) | Huidouba extract traditional Chinese medicine preparation for treating diabetes | |
CN100396295C (en) | Medicine for treating virus hepatitis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: HAINAN WANZHOU GREEN PHARMACY CO., LTD. Free format text: FORMER OWNER: KUANG JIXIAN Effective date: 20080523 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20080523 Address after: Underwater sound code of Le Town, Hainan City, Wanning Province: 571500 Applicant after: Hainan Wanzhou Green Pharmaceutical Co., Ltd. Address before: Hainan province Haikou City Jinlong Road No. 85 Lilongwe garden room C#-[3]-1301 post encoding: 570126 Applicant before: Kuang Jixian |
|
ASS | Succession or assignment of patent right |
Owner name: HAINAN WANZHOU GREEN PHARMACY CO., LTD.; APPLICAN Free format text: FORMER OWNER: HAINAN WANZHOU GREEN PHARMACY CO., LTD. Effective date: 20080808 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20080808 Address after: Underwater sound code of Le Town, Hainan City, Wanning Province: 571500 Applicant after: Hainan Wanzhou green Pharmaceutical Co., Ltd. Co-applicant after: Liang Zetai Address before: Underwater sound code of Le Town, Hainan City, Wanning Province: 571500 Applicant before: Hainan Wanzhou Green Pharmaceutical Co., Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Haerbin Dongfang Pharmaceutical Co., Ltd. Assignor: Liang Zetai Contract fulfillment period: 2009.11.28 to 2011.11.27 Contract record no.: 2010990000026 Denomination of invention: Medicinal composition containing scutellaria glucoside and bupleurum and its preparation method Granted publication date: 20090715 License type: General permission Record date: 2010.1.13 |
|
LIC | Patent licence contract for exploitation submitted for record |
Free format text: COMMON LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2009.11.28 TO 2011.11.27; CHANGE OF CONTRACT Name of requester: HARBIN DONGFANG PHARMACY CO., LTD. Effective date: 20100113 |
|
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Yangtze River Pharmaceutical Co., Ltd. Assignor: Liang Zetai Contract record no.: 2012990000168 Denomination of invention: Medicinal composition containing scutellaria glucoside and bupleurum and its preparation method Granted publication date: 20090715 License type: Common License Open date: 20051026 Record date: 20120331 |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20181214 Address after: 225300 No. 9, Longfeng Tang Road, Yongan Town, Taizhou, Jiangsu. Co-patentee after: Yangtze River Pharmaceutical Co., Ltd. Patentee after: Yangzi Pharmaceutical Group Jiangsu Longfeng traditional Chinese Medicine Co., Ltd. Address before: 571500 Water Sound of Lelai Town, Wanning City, Hainan Province Co-patentee before: Liang Zetai Patentee before: Hainan Wanzhou Green Pharmaceutical Co., Ltd. |